Félix Guerrero-Ramos, MD, PhD, FEBU, discusses key findings from the phase 3 POTOMAC trial and other studies of BCG/ICI combinations in high-risk NMIBC.
Evolving treatment paradigms in high-risk NMIBC
Bradley McGregor, MD, contextualizes recent data on emerging treatment regimens in high-risk, BCG-naïve NMIBC.
John P. Sfakianos, MD, outlines the scientific rationale for combining systemic immunotherapy with BCG in the BCG-naïve NMIBC setting.
Although BCG has been the standard of care for decades and remains the most effective available treatment, outcomes remain suboptimal for many patients.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants 510(k) clearance to Break Wave lithotripsy device for kidney stones
2
Practical guide to female pelvic organ–sparing radical cystectomy
3
CaverSTIM device shows initial promise for post-prostatectomy erectile dysfunction
4
Lina Posada Calderon, MD, provides insights on germline BAP1–associated renal cell carcinoma
5